Click-to-Release Reactions

Emerging Clinical Trials Drug Delivery

Overview

Click-to-Release reactions represent an emerging class of bioorthogonal transformations in which a click reaction is harnessed not merely to form a bond, but to trigger the cleavage of a protecting group or linker, enabling controlled release or activation of biomolecules. This concept extends click chemistry from "click-to-connect" to "click-to-activate," opening revolutionary possibilities in targeted drug delivery, prodrug activation, and controlled biomolecule decaging.

The most clinically advanced click-to-release systems are based on the tetrazine/TCO (trans-cyclooctene) IEDDA reaction. In these systems, a therapeutic molecule (drug, protein, nucleic acid) is masked by attachment to a TCO group, rendering it biologically inactive. When a tetrazine trigger is introduced — for example, at a tumor site — the ultra-fast IEDDA reaction between the tetrazine and the TCO moiety initiates a cascade of chemical transformations that releases the active molecule from its caged form.

This approach offers unprecedented spatial and temporal control over drug activity, potentially solving the central challenge of chemotherapy: delivering toxic drugs selectively to cancer cells while sparing healthy tissue.

Reaction Diagram

Key Properties

Key Mechanisms

Tetrazine-Triggered Decaging

The most widely used click-to-release mechanism exploits the IEDDA reaction between a tetrazine and a TCO-caged molecule. The design involves three key components:

1. Active molecule (cargo): The drug, fluorophore, protein, or nucleic acid to be released.
2. Self-immolative linker: A molecular spacer that connects the cargo to the TCO cage. Upon IEDDA reaction, the linker undergoes spontaneous fragmentation (1,4- or 1,6-elimination), releasing the cargo in its native form. Common linkers include p-aminobenzyl alcohol (PAB), carbamate, and carbonate spacers.
3. TCO cage: The trans-cyclooctene group that masks the cargo's activity and serves as the click reaction partner for tetrazine.

When the tetrazine encounters the TCO-caged molecule, the IEDDA reaction forms a dihydropyrazine intermediate. This transformation changes the electronic properties of the TCO moiety, triggering the self-immolative cascade that liberates the free cargo molecule. The entire process — from click reaction to cargo release — can occur within seconds to minutes.

Self-Immolative Linkers

Self-immolative linkers are molecular spacers designed to undergo spontaneous, sequential fragmentation once an initiating event (the click reaction) removes a stabilizing group. The most common designs include:

• p-Aminobenzyl alcohol (PAB) linkers: The IEDDA reaction unmasks a free amine on the PAB group, triggering a 1,6-elimination that releases CO₂ and the attached cargo. Widely used for amine-containing drugs (e.g., doxorubicin).
• Carbamate linkers: Cleavage of the carbamate linkage releases the amine cargo along with CO₂. Suitable for amine-masked prodrugs.
• Carbonate linkers: Analogous to carbamate but release alcohol-containing cargo (e.g., paclitaxel, SN-38) through carbonate elimination.
• Double-elimination linkers: Cascading elimination steps for enhanced release efficiency and faster kinetics.

Prodrug Activation

In the prodrug activation paradigm, a cytotoxic drug is rendered inactive by attachment to a TCO cage via a self-immolative linker. The prodrug circulates systemically with minimal toxicity. When the prodrug has accumulated at the target site (e.g., tumor tissue via EPR effect or antibody targeting), a tetrazine trigger is administered locally or systemically. The IEDDA reaction between tetrazine and the TCO-caged prodrug activates the self-immolative cascade, releasing the active drug selectively at the tumor site.

Tetrazine/TCO-Based Decaging — Design Principles

Other Click-to-Release Mechanisms

Isocyanide-Based Release

Isocyanides (R-NC) can participate in click-to-release reactions through their reaction with tetrazines or other electrophilic partners. The isocyanide-tetrazine reaction generates an imine intermediate that can be designed to undergo hydrolysis, releasing the cargo. This approach offers an alternative to TCO-based decaging with different kinetics and selectivity profiles.

N-Oxide Activation

Pyridine N-oxide and related N-oxide derivatives can serve as masked functional groups that are activated through bioorthogonal reduction. While not strictly a click reaction, the concept of using a bioorthogonal trigger to convert an inactive N-oxide to a reactive pyridine represents an emerging click-to-release strategy.

Azide-Triggered Release

Azide groups can serve as triggers for cargo release through Staudinger reduction (generating an amine that initiates self-immolation) or through photolytic reduction (Staudinger-photocleavage). While less developed than tetrazine/TCO systems, azide-based click-to-release offers the advantage of very small cage groups.

Applications

Targeted Prodrug Activation

Click-to-release prodrug activation represents a paradigm shift in cancer chemotherapy. Conventional chemotherapy distributes toxic drugs throughout the body, causing severe side effects. Click-to-release enables the prodrug to circulate harmlessly until a tetrazine trigger is administered at the tumor site, where the IEDDA reaction selectively activates the drug. This approach has been demonstrated with doxorubicin, paclitaxel, and monomethyl auristatin E (MMAE) prodrugs in preclinical models, showing equivalent tumor growth inhibition with dramatically reduced systemic toxicity.

Controlled Protein Decaging

Proteins can be rendered inactive by TCO-caging of critical active-site residues (e.g., lysine amines, cysteine thiols). Addition of a tetrazine trigger decages the protein, restoring its enzymatic activity or binding function. This approach enables temporal control of protein function in cell biology experiments and could be applied to activate therapeutic proteins (e.g., cytokines, growth factors) at specific tissue sites.

Drug Delivery Systems

Click-to-release chemistry is being integrated into nanoparticle drug delivery systems, where the drug-loaded nanoparticle carries TCO-caged therapeutics. Tetrazine-functionalized targeting ligands or externally administered tetrazine triggers activate drug release specifically at the target site. This approach combines the passive targeting of nanoparticles (EPR effect) with the active chemical control of click-to-release for a dual-targeting strategy.

Fluorescent Probe Activation

Fluorogenic click-to-release probes remain non-fluorescent until they encounter their target. A TCO-caged fluorophore is activated by tetrazine, releasing the free fluorophore only at the site of interest. This approach extends the fluorogenic tetrazine concept to irreversible, signal-amplifying detection strategies.

Clinical Status

Related Reactions